Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics’ portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of: 1. Midkine antibodies with significant in vivo efficacy and toxicology studies; 2. Midkine RNA therapeutics with novel anti-cancer gene editing action; 3. MK cell therapy with direct and NK-mediated anti-cancer action; and 4. siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.
External link for Roquefort Therapeutics plc
London, GB
👇 We are delighted with the appointment of SP Angel as our broker with immediate effect. SP Angel’s well regarded life sciences team is a great fit for us as we enter the next exciting stage of growth, delivering on out-licensing deals
SP Angel is delighted to announce its appointment as Broker to Roquefort Therapeutics plc
📽 In our latest video, CEO Ajan Reginald describes our portfolio of five innovative pre-clinical programs, including the Midkine antibody program that we are licencing out to PDC CRO. #biotech #oncology #ROQ #midkine #sirna #mkcells #otcmarkets #mrna Stephen West Dr Darrin M Disley OBE Simon Sinclair Jean Marie Duvall
The PDC deal facilitates the progression of our Midkine antibody pre-clinical program into human clinical trials and validates our business model & highlights our deal making capabilities. #biotech #oncology #ROQ #midkine #antibodies #sirna #mkcells #mrna #stat6 Ajan Reginald Stephen West Dr Darrin M Disley OBE Simon Sinclair Jean Marie Duvall
We are very excited to announce the signing of a term sheet for the out-licensing of our Midkine antibody portfolio to PDC CRO, a leading MEA pharmaceutical research and development organisation with a track record of successfully conducting over 150 clinical trials. PDC CRO is a great partner with a strong track record of completing clinical trials and we are confident they will accelerate development of the Midkine antibodies into the clinic. Upon a successful Phase 1 exit, this would create significant returns. We believe this is a great deal for all parties, validates our business model and highlights our deal making capabilities. We expect to conclude this licensing agreement as soon as possible. #biotech #oncology #ROQ #midkine #antibodies #sirna #mkcells #otcmarkets #mrna Ajan Reginald Stephen West Dr Darrin M Disley OBE M Disley OBE Simon Sinclair Jean Marie Duvall
🎬 In our latest video our CEO Ajan Reginald outlines 3️⃣ three key reasons to follow ROQ and to join us on our journey - where we take breakthrough innovation, Nobel prize 🏅 winning science and make medicines that will help the patients that need this the most #biotech #oncology #ROQ #midkine #sirna #mkcells #otcmarkets #mrna Stephen West Dr Darrin M Disley OBE Simon Sinclair Jean Marie Duvall
👇 In our latest video, our CEO Ajan Reginald describes the value creation strategy of the company #biotech #oncology #ROQ #midkine #sirna #mkcells #otcmarkets #mrna Stephen West Dr Darrin M Disley OBE Simon Sinclair Jean Marie Duvall
📽 A short video describing what we do here at Roquefort Therapeutics and how we are working to create value for our shareholders #biotech #oncology #ROQ #midkine #sirna #mkcells #otcmarkets #mrna Ajan Reginald Stephen West Dr Darrin M Disley OBE Simon Sinclair Jean Marie Duvall
👇Today we released our 2023 Annual Report and Financial Statements. 2023 was another busy year for the team where we delivered on a number of significant milestones. 🎯 We are now focused on 2024, which is the year where all our hard work will come together! #biotech #oncology #ROQ #midkine #sirna #mkcells #otcmarkets #mrna Ajan Reginald Stephen West Dr Darrin M Disley OBE Simon Sinclair Jean Marie Duvall https://lnkd.in/eensG-P5
Roquefort Therapeutics plc reposted this
Roquefort Therapeutics plc (LSE:ROQ, OTCQB:ROQAF) said the significant preclinical progress has positioned it to begin out-licensing discussions with major #pharmaceutical companies and private equity funds across the United States, Europe, and Japan. In an update alongside its prelims, the chief executive Ajan Reginald said: "In 2023 we delivered on our strategy by meeting our pre-clinical milestones and significantly advancing our entire portfolio. More at #Proactive #ProactiveInvestors http://ow.ly/Yk51105qT7h #LSE #OTCQB #ROQ #ROQAF
👉 Today our CEO Ajan Reginald is Lead Moderator at the Evolution European Summit in Montreux, Switzerland where Roquefort Therapeutics joins an elite gathering of Clinical Research & Trial Senior Executives from leading pharmaceutical and biotechnology companies including Johnson & Johnson, Roche, Amgen, MSD, Ipsen, and Novartis #biotech #oncology #ROQ #midkine #sirna #mkcells #otcmarkets #rna
An elite gathering of Clinical Research & Trial Senior Executives that are committed to shape the future of the industry. Foremost leaders in pharmaceuticals and biotechnology will meet in Montreux for in-depth discussions on all aspects of drug development. For more details contact me at carolinaa@marcusevanscy.com. #EvolutionSummit #ClinicalResearch #ClinicalTrials #DrugDevelopment